Sumitomo Pharma
Basic Information
- Stock Code
- 4506
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Osaka Prefecture
- Establishment Year
- May 1897
- Listing Year
- May 1949
- Official Website
- https://www.sumitomo-pharma.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Sumitomo Chemical, Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharma, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings
Overview
Sumitomo Pharma is a major pharmaceutical company founded in 1897, with strengths in the psychoneurological, diabetes, and rare disease areas, and is a Sumitomo Chemical group company expanding globally.
Current Situation
Sumitomo Pharma recorded consolidated sales of approximately 1.4827 trillion yen and operating profit of approximately 83.2 billion yen in the fiscal year ended March 2021, maintaining a stable financial base. Its main business is prescription pharmaceuticals, focusing on psychoneurological, diabetes, and specialty areas while sustaining high competitiveness domestically and internationally. It is actively advancing global expansion by establishing multiple subsidiaries in the US and Asia to develop markets. In R&D, it focuses on regenerative/cell therapies, anticancer agents, and novel drug discovery, promoting technological innovation. It actively addresses environmental and social challenges through sustainable manufacturing processes and community contributions. In 2022, it changed its name to Sumitomo Pharma to strengthen unity within the Sumitomo Group. It aims for innovative pharmaceutical creation and sustainable growth toward 2030.
Trivia
Interesting Facts
- Formed current entity through merger of Dainippon Sumitomo Pharma and Sumitomo Pharma
- Former Dainippon's Marupi mark is famous in the industry
- Historically linked to medical supply of stimulants
- Domestic pioneer aggressively focusing on regenerative medicine
- Early leader in iPS cell pharmaceutical research ahead of peers
- Historic pharmaceutical company listed on Tokyo Stock Exchange Prime
- Global company with numerous subsidiaries in Europe, Americas, and Asia
- Manufactures and sells pharmaceuticals across diverse disease areas
- Has acquired multiple US biotech ventures as subsidiaries
- Develops sustainable manufacturing and environmentally considerate technologies
- Maintains traditionally high R&D investments
- TV commercials have long contributed to corporate image enhancement
- Sumitomo Chemical is the largest shareholder with over 51%
- Actively conducts subsidiary reorganizations and name changes
- Multiple manufacturing sites domestically and internationally
Hidden Connections
- Closely linked in capital and business with Sumitomo Chemical, Sumitomo Mitsui Banking, and other Sumitomo Group companies.
- Has technology partnerships and competitive relationships with Chugai Pharmaceutical and Daiichi Sankyo in the pharma industry.
- Utilizes multiple US and Asian subsidiaries for international expansion.
- Possesses advanced technology specialized in regenerative medicine and cell pharmaceuticals in R&D.
- Has long years of sales experience in antipsychotic markets in Europe and Americas.
- Former Dainippon's 'Marupi mark' brand is a significant industry legacy.
- Actively expanding contract development and manufacturing (CDMO) business beyond drug discovery.
- Contributes to market awareness, including among medical professionals, through TV ads and sponsorships.
Future Outlook
Growth Drivers
- Progress in new drug development in psychoneurological areas
- Diversification and rising demand for diabetes treatments
- Commercial rollout of regenerative/cell pharmaceutical technology
- Accelerated global expansion and new market development
- Biopharmaceutical market expansion
- Increasing medical needs corresponding to aging society
- Efficiency improvements via AI/digital technology introduction
- Growing demand for rare disease treatments
- Strengthened response to environmental and social responsibilities
- Expanded R&D through collaborations and partnerships
- Risk diversification through diversified treatment areas
- Cost reductions via advanced manufacturing technology
Strategic Goals
- Creation of innovative CNS pharmaceuticals
- Commercialization and market securing of regenerative medicine products
- Sales expansion in global pharmaceutical markets
- Sustainable management and environmental impact reduction
- Utilization of diverse talent and organizational strengthening
- Promotion of digital transformation
- Expansion of medical solutions through collaborations
- Launch of novel anticancer agents and rare disease drugs
- Growth promotion of contract manufacturing business (CDMO)
- Deepening of social contribution activities
Business Segments
Prescription Pharmaceutical Manufacturing and Sales
- Overview
- Conducts research, manufacturing, and sales of prescription pharmaceuticals, supplying high-quality products to medical institutions domestically and internationally.
- Competitiveness
- Product development leveraging the comprehensive capabilities and expertise of the Sumitomo Chemical Group
- Customers
-
- Hospitals
- Clinics
- Medical institutions
- Pharmacies
- Pharmaceutical wholesalers
- Pharmaceutical sales agents
- Research institutions
- Medical corporations
- National/public hospitals
- Private hospitals
- University hospitals
- Clinical trial sponsors
- Overseas sales agents
- Pharmaceutical importers/exporters
- Pharmaceutical distributors
- Products
-
- Psychoneurological pharmaceuticals
- Diabetes treatments
- Anticancer agents
- Blood-related products
- Liver disease treatments
- Antibiotics
- Rare disease treatments
- Gastrointestinal function improvers
- Immunosuppressants
- Regenerative medicine products
- Vaccines
- Diagnostic agents
- Veterinary pharmaceuticals
- Biopharmaceuticals
- Gene therapy drugs
Veterinary Pharmaceuticals, Biopharmaceuticals, Regenerative Medicine Products
- Overview
- Provides specialized product development and contract manufacturing services in veterinary medicine and regenerative medicine.
- Competitiveness
- Integration of advanced cell technology and global network
- Customers
-
- Veterinary clinics
- Animal hospitals
- Livestock producers
- Biotech ventures
- Regenerative medicine facilities
- Medical institution R&D departments
- Pharmaceutical partner companies
- University research facilities
- Cell therapy developers
- Pharmaceutical manufacturers
- Overseas subsidiaries
- Veterinary drug wholesalers
- Products
-
- Veterinary antibiotics
- Regenerative cell pharmaceuticals
- Cell culture technology
- Gene-modified pharmaceuticals
- Biopharmaceutical contract manufacturing
- Regenerative medicine formulations
- Veterinary vaccines
- Cell therapy equipment
- Veterinary disinfectants
- Clinical trial pharmaceuticals
- Gene therapy-related products
Pharmaceutical Development and Manufacturing Contract (CDMO)
- Overview
- Offers integrated services from pharmaceutical development to manufacturing, achieving efficient production support.
- Competitiveness
- Advanced manufacturing technology incorporating regenerative medicine
- Customers
-
- Domestic and overseas pharmaceutical companies
- Biotechnology companies
- Research institutions
- Pharmaceutical development ventures
- Formulation contractors
- Clinical trial contractors
- Patent holders
- University R&D departments
- Generic drug manufacturers
- Overseas pharmaceutical partners
- Products
-
- Formulation development
- Cell culture technology
- API manufacturing
- Quality control
- Clinical supply
- Analytical development
- Biopharmaceutical manufacturing
- Generic formulations
- Biosimilars
- Process development
Overseas Sales and Marketing
- Overview
- Builds sales channels tailored to each country's market and conducts marketing activities to promote product penetration.
- Competitiveness
- Market adaptability utilizing local subsidiaries
- Customers
-
- Overseas pharmaceutical companies
- Pharmaceutical wholesalers
- Local sales agents
- International medical institutions
- Multinational insurers
- R&D partners
- Regulatory authorities
- Overseas pharmaceutical evaluation bodies
- Products
-
- Prescription pharmaceuticals in general
- Rare disease drugs
- Anticancer agents
- Diabetes drugs
- Psychoneurological drugs
- Regenerative medicine products
R&D Partnerships
- Overview
- Collaborates with academic institutions and companies to advance innovative pharmaceutical creation.
- Competitiveness
- Advanced research capabilities and global collaboration network
- Customers
-
- Biotech ventures
- University research institutions
- Pharmaceutical companies
- International joint research teams
- Technology providers
- Clinical research facilities
- Patent management organizations
- Products
-
- Novel compound development
- Clinical trial research
- Therapeutic mechanism research
- Regenerative medicine technology
- AI drug discovery technology
- Gene therapy development
Competitive Advantage
Strengths
- Stable support system from Sumitomo Chemical Group
- Expertise in psychoneurological and diabetes areas
- Global subsidiary network
- Possession of advanced regenerative medicine technology
- Rich product portfolio
- Long history and strong brand power
- Advanced R&D structure
- Comprehensive domestic and international sales network
- Technology acquisition through diverse alliances and acquisitions
- Solid financial base
- Pharmaceutical safety management and compliance
- IP protection system
- Advanced manufacturing technology
- Aggressive overseas market development
- Broad coverage of pharmaceutical categories
Competitive Advantages
- Top-class domestic capability in CNS-focused pharmaceutical development
- Advanced regenerative medicine product development using iPS cell technology
- Diversified product pipeline from merger of Dainippon and Sumitomo Pharma
- High trust among domestic and international medical institutions
- Large-scale R&D investment leveraging Sumitomo Chemical Group's capital
- Development and deployment of global talent in multinational environments
- Rapid response to market needs through diverse subsidiaries
- Established sales base in Europe, Americas, and Asia
- Product enhancement in rare diseases and oncology through multiple partnerships
- High-quality production via multifaceted manufacturing facilities
- Business operations considering sustainability and social contributions
- Ensured product safety through strict regulatory compliance
- Rapid commercialization of research outcomes
- Effective corporate governance structure
- Early adoption of new technologies and products ahead of competitors
Threats
- Increasing financial burden from rising pharmaceutical development costs
- Intensifying global competition and price wars
- Product approval delays due to stricter regulations
- Competition from new entrants and biotech ventures
- Generic drug penetration after patent expiry
- Risk of global pharmaceutical safety issues
- Revenue instability from exchange rate fluctuations
- Impact of healthcare system reforms on insurance reimbursement
- Novel infectious disease outbreaks and supply chain risks
- IP infringement risks
- Rising manufacturing costs from strengthened environmental regulations
- Intensifying competition for talent acquisition
Innovations
2024: Advancing Commercialization of Regenerative/Cell Pharmaceuticals
- Overview
- Enhancing manufacturing technology for regenerative medicine products and expanding investments toward commercialization.
- Impact
- Improved manufacturing efficiency and new market development
2023: Strengthening iPS Cell Technology Research
- Overview
- Accelerating innovative pharmaceutical development using iPS cells.
- Impact
- Expectations for rare disease treatment creation
2022: New Drug Development via Global Partnerships
- Overview
- Collaborating with numerous external partners on joint novel compound development.
- Impact
- Expanded development pipeline and risk diversification
2021: Initiating AI Utilization in Drug Discovery
- Overview
- Introducing AI technology to improve efficiency in novel drug candidate exploration.
- Impact
- Cost reduction through shortened research periods
2020: Advanced Quality Management System
- Overview
- Promoting digitalization of manufacturing processes and optimization of quality control.
- Impact
- Enhanced product safety and consistency
Sustainability
- Expanding introduction of energy-saving equipment to reduce environmental impact
- Implementing pharmaceutical waste reduction programs internally and externally
- Participating in community health promotion projects
- Promoting diversity and increasing female executive ratio
- Establishing and strengthening sustainable procurement standards
- Promoting employee health and work-style reforms
- CO2 emission reductions and carbon neutrality plans
- Promoting use of sustainable raw materials in product development
- Ongoing contributions through community support programs
- Building transparent corporate governance structure
- Promoting ethical clinical trials
- Strengthening risk management and crisis response systems